Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 32%
Hold 14%
Sell 5%
Strong Sell 9%

Bulls say

Arcturus Therapeutics Holdings Inc. possesses a promising growth trajectory, highlighted by its expanding manufacturing capabilities through a joint venture with Meiji Pharma, which is set to enhance production efficiency in Japan. The company anticipates significant near-term revenue potential, projected at over $500 million five years post-launch, particularly following the anticipated clinical data readouts in 2025 and the European Commission's recent marketing authorization for its self-amplifying mRNA COVID-19 vaccine, Kostaive. Additionally, reduced execution risk is anticipated from the partnership with CSL Seqirus, leveraging its established global commercialization expertise to drive Arcturus's market penetration and financial performance.

Bears say

Arcturus Therapeutics Holdings Inc. has significantly revised its revenue projections for the upcoming COVID-19 season, with Kostaive revenue estimates slashed from $156.4 million to $11.8 million, reflecting a drastic reduction in anticipated vaccination doses in Japan. The company reported a net loss of $30 million for the fourth quarter of 2024, coupled with an unfavorable financial outlook stemming from rising operating expenses. Furthermore, the stock's valuation remains heavily reliant on the success of its lead asset, ARCT-154, in the face of significant trial and regulatory risks, casting doubt on its ability to sustain operations and achieve future profitability.

Arcturus Therapeutics (ARCT) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 32% recommend Buy, 14% suggest Holding, 5% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 22 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Jun 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.